{"text": "Among patients who received rhNGF, 418 (83%) completed the regimen compared with 461 (90%) who received placebo.", "user_data": {"pmid": "11056593"}}
{"text": "Administration of rhNGF was safe, with few adverse events attributed to treatment apart from injection site pain/hyperalgesia and other pain syndromes.", "user_data": {"pmid": "11056593"}}
{"text": "However, neither the primary end point (P =.25) nor most of the secondary end points demonstrated a significant benefit of rhNGF.", "user_data": {"pmid": "11056593"}}
{"text": "Exceptions were the global symptom assessment (P =.03) and 2 of 32 comparisons within the PBQ, which showed a modest but significant benefit of rhNGF (P =.05 for severity of pain in the legs and P =.003 for 6-month symptoms in the feet and legs).", "user_data": {"pmid": "11056593"}}
{"text": "The patients were assigned to two groups.", "user_data": {"pmid": "11196396"}}
{"text": "Twenty-six patients, aged 21 to 36 years (mean age 27), received only fluoxetine 20 mg/day (1 capsule) for a week which was later increased to 40 mg/day (2 capsules).", "user_data": {"pmid": "11196396"}}
{"text": "Seventeen patients, aged 19 to 48 years (mean age 31), were given fluoxetine 20 mg/day plus local application of lidocaine ointment.", "user_data": {"pmid": "11196396"}}
{"text": "The patients and partners were re-evaluated 8 weeks after the treatment.", "user_data": {"pmid": "11196396"}}
{"text": "The results were classified as unsuccessful, improvement and cure.", "user_data": {"pmid": "11196396"}}
{"text": "The chi-square test was used for statistical analysis.", "user_data": {"pmid": "11196396"}}
{"text": "In the fluoxetine group, 8 (30.8%) patients cured, 11 (42.2%) showed improvement and there were 7 failures (26.9%).", "user_data": {"pmid": "11196396"}}
{"text": "In the combination treatment group, 9 (52.9%) patients cured, improvement was observed in 5 (29.4%) and failure in 3 (17.6%).", "user_data": {"pmid": "11196396"}}
{"text": "Side effects in group I were observed in 6 patients (23%) and in 5 (29.4%) in group II.", "user_data": {"pmid": "11196396"}}
{"text": "There were no statistical differences between the two groups according to the side effects (p > 0.01).", "user_data": {"pmid": "11196396"}}
{"text": "No patients were excluded from the study due to side effects.", "user_data": {"pmid": "11196396"}}
{"text": "There were significantly more responders in the acarbose-treated group compared with the placebo group (20/24 patients vs. 10/19 patients; p < 0.05).", "user_data": {"pmid": "11228756"}}
{"text": "The mean daily insulin dose after 24 weeks of treatment was 16.4 +/- 10.1 IU in the acarbose group and 22.4 +/- 12.2 IU in the placebo group (mean +/- s.d.; p < 0.07).", "user_data": {"pmid": "11228756"}}
{"text": "Postprandial increases in blood glucose, insulin and C-peptide were consistently lower in the acarbose-treated group than in the placebo group.", "user_data": {"pmid": "11228756"}}
{"text": "For example, the mean increase in 2-h postprandial serum insulin remained almost unchanged in the acarbose group at the end of 24 weeks of treatment compared to an increase to 43 +/- 29 microU/ml (mean +/- s.d.) at the end of the study period for the placebo group.", "user_data": {"pmid": "11228756"}}
{"text": "The infusions produced similar nicotine levels in both groups.", "user_data": {"pmid": "11422660"}}
{"text": "In the absence of nicotine, DM2 were more insulin resistant than Ctr (6.7 +/- 0.4 vs. 10.9 +/- 0.3 mg kg-1 LBM min(-1), respectively; P < 0.0001).", "user_data": {"pmid": "11422660"}}
{"text": "This insulin resistance was further aggravated by the nicotine infusion in DM2 but not in Ctr (4.6 +/- 0.3 vs. 10.9 +/- 0.3 mg kg(-1) LBM min(-1); P < 0.0001).", "user_data": {"pmid": "11422660"}}
{"text": "Only minor differences were seen in FFA levels, pulse rates and blood pressure.", "user_data": {"pmid": "11422660"}}
{"text": "At month 12, biopsy-confirmed acute rejections were reported for 15.2% (induction) and 30.4% (noninduction) of patients (P=0.001).", "user_data": {"pmid": "11579299"}}
{"text": "The incidence of steroid-sensitive acute rejections was 7.9% (induction) and 22.2% (noninduction)(P=0.001).", "user_data": {"pmid": "11579299"}}
{"text": "Steroid-resistant acute rejections were reported for 8.6% (induction) and 8.9% (noninduction) of patients.", "user_data": {"pmid": "11579299"}}
{"text": "A total of nine patients died.", "user_data": {"pmid": "11579299"}}
{"text": "Patient survival and graft survival at month 12 was similar in both treatment groups (97.4% vs. 96.8% and 92.1% vs. 91.1%, respectively).", "user_data": {"pmid": "11579299"}}
{"text": "Statistically significant differences in the incidence of adverse events were found for cytomegalovirus (CMV) infection (induction, 32.5% vs. noninduction, 19.0%, P=0.009), leukopenia (37.3% vs. 9.5%, P<0.001), fever (25.2% vs. 10.1%, P=0.001), herpes simplex (17.9% vs. 5.7%, P=0.001), and thrombocytopenia (11.3% vs. 3.2%, P=0.007).", "user_data": {"pmid": "11579299"}}
{"text": "In the induction group, serum sickness was observed in 10.6% of patients.", "user_data": {"pmid": "11579299"}}
{"text": "The incidence of new onset diabetes mellitus was 3.4% (induction) and 4.5% (noninduction).", "user_data": {"pmid": "11579299"}}
{"text": "Mean blood pressure fell to 146/79 mm Hg (17/11) in losartan patients and 148/79 mm Hg (19/11) in atenolol patients.", "user_data": {"pmid": "11937179"}}
{"text": "The primary endpoint occurred in 103 patients assigned losartan (n=586) and 139 assigned atenolol (n=609); relative risk 0.76 (95% CI 0.58-.98), p=0.031.", "user_data": {"pmid": "11937179"}}
{"text": "38 and 61 patients in the losartan and atenolol groups, respectively, died from cardiovascular disease; 0.63 (0.42-0.95), p=0.028.", "user_data": {"pmid": "11937179"}}
{"text": "Mortality from all causes was 63 and 104 in losartan and atenolol groups, respectively; 0.61 (0.45-0.84), p=0.002.", "user_data": {"pmid": "11937179"}}
{"text": "As the drop-out rate after crossover was high (17 of 79 patients [22%]), we analyzed the trial as a parallel clinical trial, using data of the first half of the crossover phase only.", "user_data": {"pmid": "12401759"}}
{"text": "At 16 weeks, mean HbA(1c) was 0.84% (95% CI -1.31 to -0.36) lower in the continuous subcutaneous insulin infusion group compared with the insulin injection group (P = 0.002).", "user_data": {"pmid": "12401759"}}
{"text": "Stability of blood glucose self-measurement values, expressed as SD of the nine-point blood glucose profiles, improved in the insulin pump group by 29.3 +/- 41.1 vs. 8.2 +/- 36.5% in the injection group (P = 0.039).", "user_data": {"pmid": "12401759"}}
{"text": "The number of mild hypoglycemic episodes per patient-week was 0.99 (95% CI 0.11-1.87) higher in the insulin pump group (P = 0.028).", "user_data": {"pmid": "12401759"}}
{"text": "Weight gain was similar in both groups.", "user_data": {"pmid": "12401759"}}
{"text": "Scores on the Short-Form 36-Item subscales 'general health' and 'mental health' improved in the continuous subcutaneous insulin infusion group, compared with stable values in the injection group (P = 0.048 and 0.050, respectively).", "user_data": {"pmid": "12401759"}}
{"text": "Blood pressure was reduced to 146/79 and 148/79 in losartan-treated patients and atenolol-treated patients, respectively.", "user_data": {"pmid": "12599844"}}
{"text": "The primary endpoint occurred in 103 patients assigned losartan (n = 586) and 139 assigned atenolol (n = 609).", "user_data": {"pmid": "12599844"}}
{"text": "Relative risk reduction 24% (p < 0.031).", "user_data": {"pmid": "12599844"}}
{"text": "Cardiovascular mortality was reduced by 37% in favour of losartan (p < 0.028), and all cause mortality by 39% (p < 0.002).", "user_data": {"pmid": "12599844"}}
{"text": "Glycaemia was significantly lower in the clonidine group (P<0.01) and the median amount of insulin administered was significantly reduced: clonidine group 9.0 (interquartile range 5.1) units; control 18.6 (10.2) units; P<0.01).", "user_data": {"pmid": "12644413"}}
{"text": "Plasma catecholamine concentrations were lower in patients given clonidine (P<0.05) but there was no difference in cortisol concentrations.", "user_data": {"pmid": "12644413"}}
{"text": "Two hundred forty-four patients (125 women, 119 men; all but 1 Hispanic) were randomized to receive pioglitazone (n = 121) or glimepiride (n = 123).", "user_data": {"pmid": "15220012"}}
{"text": "In the intent-to-treat sample, pioglitazone and glimepirede produced comparable reductions in HbA(1c) from baseline to the end of the study (-0.78% and -0.68%, respectively).", "user_data": {"pmid": "15220012"}}
{"text": "The pioglitazone group had significantly higher HbA(1c) values compared with the glimepiride group after 12 weeks of therapy (8.66% vs 7.80%; P = 0.007) but had significantly lower values after 52 weeks (7.46% vs 7.77%; P = 0.027).", "user_data": {"pmid": "15220012"}}
{"text": "Pioglitazone significantly reduced FPG compared with glimepiride (-0.6 vs 0.6 mmol/L; P = 0.01).", "user_data": {"pmid": "15220012"}}
{"text": "Pioglitazone therapy was associated with significant increases in insulin sensitivity (reduced insulin resistance), whereas glimepiride had no effect.", "user_data": {"pmid": "15220012"}}
{"text": "HOMA-S values changed 18.0% for pioglitazone and -7.9% for glimepiride (P < 0.001), QUICKI values changed a respective 0.013 and -0.007 (P < 0.001), and FSI values were -21.1 and 15.1 pmol/L (P< 0.001).", "user_data": {"pmid": "15220012"}}
{"text": "Both drugs were well tolerated, with pioglitazone associated with more peripheral edema (number of treatment-emergent cases: 35/121[28.9%] vs 17/123 [13.8%]; P = 0.005) and fewer hypoglycemic episodes (19 [15.7%] vs 38 [30.9%]; P = 0.024).", "user_data": {"pmid": "15220012"}}
{"text": "The incidence of weight gain was not significantly different between treatment groups.", "user_data": {"pmid": "15220012"}}
{"text": "Overall, 9 (69%) of 13 patients noted subjective improvement after BTX-A treatment.", "user_data": {"pmid": "15533466"}}
{"text": "The Interstitial Cystitis Symptom Index and Interstitial Cystitis Problem Index mean scores improved by 71% and 69%, respectively (P <0.05).", "user_data": {"pmid": "15533466"}}
{"text": "Daytime frequency, nocturia, and pain by visual analog scale decreased by 44%, 45%, and 79%, respectively (P <0.01).", "user_data": {"pmid": "15533466"}}
{"text": "The first desire to void and maximal cystometric capacity increased by 58% and 57%, respectively (P <0.01).", "user_data": {"pmid": "15533466"}}
{"text": "Among all HOPE patients, there were no significant differences in the primary analysis: for cancer incidence, there were 552 patients (11.6%) in the vitamin E group vs 586 (12.3%) in the placebo group (relative risk [RR], 0.94; 95% confidence interval [CI], 0.84-1.06; P = .30); for cancer deaths, 156 (3.3%) vs 178 (3.7%), respectively (RR, 0.88; 95% CI, 0.71-1.09; P = .24); and for major cardiovascular events, 1022 (21.5%) vs 985 (20.6%), respectively (RR, 1.04; 95% CI, 0.96-1.14; P = .34).", "user_data": {"pmid": "15769967"}}
{"text": "Patients in the vitamin E group had a higher risk of heart failure (RR, 1.13; 95% CI, 1.01-1.26; P = .03) and hospitalization for heart failure (RR, 1.21; 95% CI, 1.00-1.47; P = .045).", "user_data": {"pmid": "15769967"}}
{"text": "Similarly, among patients enrolled at the centers participating in the HOPE-TOO trial, there were no differences in cancer incidence, cancer deaths, and major cardiovascular events, but higher rates of heart failure and hospitalizations for heart failure.", "user_data": {"pmid": "15769967"}}
{"text": "Coadministration of enalapril-compared with placebo-resulted in a temporarily higher metabolic effect of glibenclamide (AUC GIR(0-120)229 +/- 173 vs 137 +/- 44 mg kg(-1), p < 0.01; mean +/- SD), which lasted from 120 min to 240 min after enalapril administration.", "user_data": {"pmid": "15915547"}}
{"text": "In parallel, the maximal metabolic effect of glibenclamide tended to be higher with enalapril (GIR(max)5.2 +/- 1.9 vs 4.1 +/- 1.3 mg kg(-1) min(-1); p = 0.19).", "user_data": {"pmid": "15915547"}}
{"text": "However, the total metabolic effect of glibenclamide was almost identical between volunteers taking enalapril or placebo (AUC GIR(0-600)1267 +/- 334 vs 1286 +/- 249 mg kg(-1), ns).", "user_data": {"pmid": "15915547"}}
{"text": "In contrast, serum insulin levels, C-peptide levels, and serum glibenclamide profiles were not significantly different between enalapril and placebo.", "user_data": {"pmid": "15915547"}}
{"text": "In both groups, HV and HV standard deviation score HV-SDSCA increased during treatment and decreased during observation periods.", "user_data": {"pmid": "16772718"}}
{"text": "Interruption of treatment in the TOTO group did not result in a better gain in height standard deviation score H-SDSCA when compared with the TTOO group.", "user_data": {"pmid": "16772718"}}
{"text": "After 4 years of study, the gain in H-SDSCA was 1.4 + or - 01 in the TOTO group and 1.6 + or - 0.2 in the TTOO group leading to a mean height of -2.0 + or - 1.0 SDS and -2.0 + or - 0.8 SDS, respectively.", "user_data": {"pmid": "16772718"}}
{"text": "The rate of bone maturation was similar in the two groups.", "user_data": {"pmid": "16772718"}}
{"text": "Both bone dehiscence and superficial wound instability were less frequent in the PDS Group (4 and 3 cases in the SS Group, respectively, vs. no cases in the PDS Group).", "user_data": {"pmid": "17073957"}}
{"text": "Cox proportional hazards regression model in the whole study population identified female sex, chronic renal insufficiency, diabetes, advanced age, lower sternal thickness, osteoporosis, corticosteroid therapy, and prolonged CPB or ventilation times as predisposing factors to any of the two studied sternal complications.", "user_data": {"pmid": "17073957"}}
{"text": "56 patients were randomly assigned to each group, median follow-up was 26.5 months (interquartile range, 40), and patients in the diet group spent a median of 10.7 months (interquartile range, 11) following an sVLPD.", "user_data": {"pmid": "17472838"}}
{"text": "Forty patients in the diet group started dialysis treatment because of either fluid overload or hyperkalemia.", "user_data": {"pmid": "17472838"}}
{"text": "There were 31 deaths (55%) in the dialysis group and 28 deaths (50%) in the diet group.", "user_data": {"pmid": "17472838"}}
{"text": "One-year observed survival rates at intention to treat were 83.7% (95% confidence interval [CI], 74.5 to 94.0) in the dialysis group versus 87.3% (95% CI, 78.9 to 96.5) in the diet group (log-rank test for noninferiority, P < 0.001; for superiority, P = 0.6): the difference in survival was -3.6% (95% CI, -17 to +10; P = 0.002).", "user_data": {"pmid": "17472838"}}
{"text": "The hazard ratio for hospitalization was 1.50 for the dialysis group (95% CI, 1.11 to 2.01; P < 0.01).", "user_data": {"pmid": "17472838"}}
{"text": "On the primary efficacy endpoint, sildenafil-treated subjects had significantly better scores on the International Index of Erectile Function (IIEF) questions 3 and 4 than placebo (p < 0.001, both questions).", "user_data": {"pmid": "17624203"}}
{"text": "When accumulated into IIEF domains, all five domains were significant in favor of sildenafil.", "user_data": {"pmid": "17624203"}}
{"text": "In addition, sildenafil-treated subjects were more satisfied with treatment and had a higher intercourse success rate.", "user_data": {"pmid": "17624203"}}
{"text": "The majority of adverse events were mild in severity; the most commonly reported treatment-related events were dizziness (7.7%) and tinnitus (2.9%).", "user_data": {"pmid": "17624203"}}
{"text": "Endothelial function significantly improved after consumption of a walnut-enriched ad libitum diet compared with that after consumption of an ad libitum diet without walnuts (2.2 +/- 1.7 vs. 1.2 +/- 1.6%; P = 0.04).", "user_data": {"pmid": "19880586"}}
{"text": "The walnut-enriched diet increased fasting serum glucose and lowered serum total cholesterol and LDL cholesterol from baseline (10.0 +/- 20.5 mg/dl, P = 0.04; -9.7 +/- 14.5 mg/dl, P < 0.01; and -7.7 +/- 10 mg/dl, P < 0.01, respectively), although these changes were not significant compared with those for an ad libitum diet without walnuts.", "user_data": {"pmid": "19880586"}}
{"text": "There were no significant changes in anthropometric measures, plasma A1C, and insulin sensitivity.", "user_data": {"pmid": "19880586"}}
{"text": "There was no significant difference in change in BP between intervention and control; BP -4.2 mmHg (95% CI -12.4 to 3.9)/-2.6 mmHg (95% CI -8.4 to 3.3).", "user_data": {"pmid": "19919399"}}
{"text": "This result did not alter in post hoc analyses, when patients not achieving target breathing frequency (<10 breaths/min) or non-compliant patients were excluded.", "user_data": {"pmid": "19919399"}}
{"text": "QoL did not change over time.", "user_data": {"pmid": "19919399"}}
{"text": "Both groups were similar regarding age (p = 0.06, Mann-Whitney test).", "user_data": {"pmid": "19958108"}}
{"text": "Mean pupil diameter in group 0 was 8.57 and 8.73 in group 1.", "user_data": {"pmid": "19958108"}}
{"text": "There was no statistic difference between both groups (p = 0.44).", "user_data": {"pmid": "19958108"}}
{"text": "Pupil diameter was greater than 7 mm in all patients (100%).", "user_data": {"pmid": "19958108"}}
{"text": "Pattern scan laser and GLX required an average fluence of 40.33 vs 191 J/cm(2), respectively.", "user_data": {"pmid": "20216293"}}
{"text": "Average time required per sitting was 1.43 minutes with PASCAL and 4.53 minutes with GLX.", "user_data": {"pmid": "20216293"}}
{"text": "Average visual analog scale reading for GLX was 4.6, whereas that for PASCAL was 0.33.", "user_data": {"pmid": "20216293"}}
{"text": "Heidelberg retinal angiography images showed the spot spread as being 430 versus 310 microm at 3 months with GLX and PASCAL.", "user_data": {"pmid": "20216293"}}
{"text": "The eyes treated with PASCAL showed higher average retinal sensitivity in the central 15 degrees and 15 degrees to 30 degrees zones (25.08 and 22.08 dB, respectively) than the eyes treated with GLX (23.16 and 17.14 dB), respectively.", "user_data": {"pmid": "20216293"}}
{"text": "Mean BCVA over 6\u00a0months remained unchanged in 85% of patients of group II, and decreased in 53% of patients of group I.", "user_data": {"pmid": "21243370"}}
{"text": "Results were not statistically significant different [group I: mean decrease log MAR 95% CI (0.06; 0.32), group II: (-0.02; 0.11)].", "user_data": {"pmid": "21243370"}}
{"text": "OCT revealed a significantly greater reduction of foveal thickness following PVD with ILM removal [group I: mean change: 95% CI (-208.95\u00a0\u03bcm; -78.05\u00a0\u03bcm), group II: (-80.90\u00a0\u03bcm: +59.17\u00a0\u03bcm)].", "user_data": {"pmid": "21243370"}}
